<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12767">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456508</url>
  </required_header>
  <id_info>
    <org_study_id>DX-88/19</org_study_id>
    <nct_id>NCT00456508</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)</brief_title>
  <official_title>Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dyax Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dyax Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of repeated doses of
      ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE
      patients continued access to ecallantide. In addition, patients enrolled in DX-88/20
      (EDEMA4) trial will be followed up and treated for subsequent attacks in this trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label trial.

      The study is designed to assess the efficacy and safety of 30 mg subcutaneous ecallantide in
      the treatment of acute attacks of hereditary angioedema. This study is designed to provide
      efficacy and safety data on repeated use of ecallantide. These data are intended to support
      the marketing authorization of ecallantide in the treatment of acute attacks of hereditary
      angioedema. Efficacy and safety of ecallantide will be evaluated in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing</measure>
    <time_frame>4 hrs post dose after every episode</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean Symptom Complex Severity (MSCS) score is a validated point-in-time measure of symptom severity. At baseline and 4 hrs, patients rated the severity on a categorical scale (0=normal, 1=mild, 2=moderate, 3=severe) for symptoms at each affected anatomical location. Ratings were averaged to obtain the MSCS score. A decrease in MSCS score reflected an improvement in symptoms; clinically meaningful improvement was indicated by a reduction in the score of 0.30 or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Outcome Score (TOS) at 4 Hrs Post Dosing, Based on the Patient Assessment of Baseline Severity of Symptoms</measure>
    <time_frame>4 hrs post dose after every episode</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Treatment Outcome Score (TOS)is a validated measure of response to therapy. Response assessment for each symptom complex (internal head/neck, stomach/GI, genital/buttocks, external head/neck or cutaneous) was to be weighted based on the severity of symptom complexes at baseline. Severity assessment at baseline was rated on a categorical scale (1=mild, 2=moderate, 3=severe) for symptoms at each affected symptom complex. Response assessment of each symptom complex post-dosing relative to baseline used a scale (100=significant improvement, 50=improvement, 0=same). The weighted values were used to calculate the composite TOS. A TOS greater than 0 denotes an improvement in symptoms compared with baseline severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Significant Improvement</measure>
    <time_frame>15 min - 4 hrs post dose after every episode</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to significant improvement in overall response based on the period from 15 minutes after dosing through 4 hrs post dosing. Significant improvement was defined as a response of &quot;a lot better or resolved&quot; in the overall response assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>DX-88 (ecallantide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ecallantide</intervention_name>
    <description>solution for SC injection, one 30 mg dose per HAE attack</description>
    <arm_group_label>DX-88 (ecallantide)</arm_group_label>
    <other_name>DX-88</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 years of age or older

          -  Documented diagnosis of HAE (Type I or II)

          -  Willing and able to give informed consent

          -  Acute HAE attack at time of presentation

        Exclusion Criteria:

          -  Receipt of an investigational drug or device, within 30 days prior to study
             treatment, other than DX-88 (ecallantide)

          -  Pregnancy or breastfeeding

          -  Receipt of non-investigational C1-INH or DX-88 within 72 hours of treatment

          -  Patients eligible for current, ongoing clinical trial in which DX 88 (ecallantide) is
             offered
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bill Pullman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dyax Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aaron Davis</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Allergy &amp; Asthma Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Coast Allergy</name>
      <address>
        <city>Crescent City</city>
        <state>California</state>
        <zip>95531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacob Offenberger</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Department of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates, P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital, Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center, Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, General Clinical Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Asthma, Allergy and Immunology Clinical Research Unit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roberson Allergy and Asthma</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy &amp; Asthma Center, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Center of Brookstone</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Consultants in Allergy and Immunology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muncie Allergy Center</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy &amp; Asthma</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Asthma and Allergy</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Institutes of Michigan</name>
      <address>
        <city>Clinton TWP</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Research Institute of Michigan, PLC</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Access to Research and Education Society</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ- New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Partners of Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Partners of Western North Carolina</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati, Division of Internal Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Allergy and Pulmonary Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Allergy and Asthma Center, PC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Paull Allergy and Asthma Clinic, P.A</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-2409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Allergy, Asthma, &amp; Immunology</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Research Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan University Hospital</name>
      <address>
        <city>Amman</city>
        <zip>1194</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Jordan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>April 4, 2007</firstreceived_date>
  <firstreceived_results_date>June 29, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DX-88 (Ecallantide)</title>
          <description>Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>DX-88 (ecallantide)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35.8" spread="14.39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="141"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Jordan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing</title>
        <description>Mean Symptom Complex Severity (MSCS) score is a validated point-in-time measure of symptom severity. At baseline and 4 hrs, patients rated the severity on a categorical scale (0=normal, 1=mild, 2=moderate, 3=severe) for symptoms at each affected anatomical location. Ratings were averaged to obtain the MSCS score. A decrease in MSCS score reflected an improvement in symptoms; clinically meaningful improvement was indicated by a reduction in the score of 0.30 or more.</description>
        <time_frame>4 hrs post dose after every episode</time_frame>
        <safety_issue>No</safety_issue>
        <population>All efficacy analyses were to be based on the safety population (all treated patients). Only those patients with non-missing severity and response assessment were included in the change in MSCS score.</population>
        <group_list>
          <group group_id="O1">
            <title>DX-88 (Ecallantide)</title>
            <description>Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing</title>
            <description>Mean Symptom Complex Severity (MSCS) score is a validated point-in-time measure of symptom severity. At baseline and 4 hrs, patients rated the severity on a categorical scale (0=normal, 1=mild, 2=moderate, 3=severe) for symptoms at each affected anatomical location. Ratings were averaged to obtain the MSCS score. A decrease in MSCS score reflected an improvement in symptoms; clinically meaningful improvement was indicated by a reduction in the score of 0.30 or more.</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 1 (n=138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.04" spread="0.773"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 2 (n=98)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.06" spread="0.731"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 3 (n=73)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.07" spread="0.801"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 4 (n=52)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.15" spread="0.791"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 5 (n=38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.16" spread="0.746"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 6 (n=32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.07" spread="0.806"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 7 (n=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.24" spread="0.797"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 8 (n=22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.31" spread="0.667"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 9 (n=22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.20" spread="0.764"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 10 (n=16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.27" spread="1.027"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 11 (n=16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.22" spread="0.643"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 12 (n=12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.36" spread="0.677"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>change in MSCS at 4 hrs episode 13 (n=12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.10" spread="0.657"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Outcome Score (TOS) at 4 Hrs Post Dosing, Based on the Patient Assessment of Baseline Severity of Symptoms</title>
        <description>The Treatment Outcome Score (TOS)is a validated measure of response to therapy. Response assessment for each symptom complex (internal head/neck, stomach/GI, genital/buttocks, external head/neck or cutaneous) was to be weighted based on the severity of symptom complexes at baseline. Severity assessment at baseline was rated on a categorical scale (1=mild, 2=moderate, 3=severe) for symptoms at each affected symptom complex. Response assessment of each symptom complex post-dosing relative to baseline used a scale (100=significant improvement, 50=improvement, 0=same). The weighted values were used to calculate the composite TOS. A TOS greater than 0 denotes an improvement in symptoms compared with baseline severity.</description>
        <time_frame>4 hrs post dose after every episode</time_frame>
        <safety_issue>No</safety_issue>
        <population>All efficacy analyses were to be based on the safety population (all treated patients). Only those patients with non-missing severity and response assessment were included in the change in TOS score.</population>
        <group_list>
          <group group_id="O1">
            <title>DX-88 (Ecallantide)</title>
            <description>Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Treatment Outcome Score (TOS) at 4 Hrs Post Dosing, Based on the Patient Assessment of Baseline Severity of Symptoms</title>
            <description>The Treatment Outcome Score (TOS)is a validated measure of response to therapy. Response assessment for each symptom complex (internal head/neck, stomach/GI, genital/buttocks, external head/neck or cutaneous) was to be weighted based on the severity of symptom complexes at baseline. Severity assessment at baseline was rated on a categorical scale (1=mild, 2=moderate, 3=severe) for symptoms at each affected symptom complex. Response assessment of each symptom complex post-dosing relative to baseline used a scale (100=significant improvement, 50=improvement, 0=same). The weighted values were used to calculate the composite TOS. A TOS greater than 0 denotes an improvement in symptoms compared with baseline severity.</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>TOS at 4 hrs for episode 1 (n=140)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69.80" spread="35.378"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 2 (n=98)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70.05" spread="40.639"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 3 (n=73)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63.08" spread="42.840"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 4 (n=52)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62.65" spread="42.802"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 5 (n=39)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.13" spread="34.858"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 6 (n=32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.42" spread="40.866"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 7 (n=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.20" spread="34.229"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 8 (n=22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79.77" spread="24.663"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 9 (n=22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71.06" spread="37.270"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 10 (n=16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.30" spread="23.556"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 11 (n=16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.94" spread="45.615"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 12 (n=13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.92" spread="43.853"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TOS at 4 hrs for episode 13 (n=12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64.93" spread="46.854"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Significant Improvement</title>
        <description>Time to significant improvement in overall response based on the period from 15 minutes after dosing through 4 hrs post dosing. Significant improvement was defined as a response of &quot;a lot better or resolved&quot; in the overall response assessment.</description>
        <time_frame>15 min - 4 hrs post dose after every episode</time_frame>
        <safety_issue>No</safety_issue>
        <population>All efficacy analyses were to be based on the safety population (all treated patients). Only those patients with non-missing severity and response assessment were included in the change in TOS score.</population>
        <group_list>
          <group group_id="O1">
            <title>DX-88 (Ecallantide)</title>
            <description>Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Significant Improvement</title>
            <description>Time to significant improvement in overall response based on the period from 15 minutes after dosing through 4 hrs post dosing. Significant improvement was defined as a response of &quot;a lot better or resolved&quot; in the overall response assessment.</description>
            <units>estimated time in minutes</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>time to improvement in min. for episode 1 (n=145)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="225.2" lower_limit="165.4" upper_limit="228.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 2 (n=102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="194.5" lower_limit="165.2" upper_limit="227.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 3 (n=77)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="225.4" lower_limit="225.1">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 4 (n=56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="198.1" lower_limit="165.4">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 5 (n=41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="240.0" lower_limit="165.3">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 6 (n=33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="225.2" lower_limit="137.0">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 7 (n=27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA" lower_limit="195.3">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 8 (n=23)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="210.5" lower_limit="135.3">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 9 (n=23)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="169.3" lower_limit="135.4" upper_limit="240.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 10 (n=17)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="170.5" lower_limit="165.1">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 11 (n=16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226.5" lower_limit="145.7">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 12 (n=15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177.2" lower_limit="113.8">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>time to improvement in min. for episode 13 (n=13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="195.2" lower_limit="135.1">N/A: significant improvement in overall response was not reached within 4 hours.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>pre-dose to 28 days (+/-2 days) post dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>DX-88 (ecallantide)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>hereditary angioedema</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>cellulitis staphyloccal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>transfusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>white blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>laryngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>homicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>hereditary angioedema</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William E. Pullman</name_or_title>
      <organization>Dyax Corp.</organization>
      <phone>617-250-2500</phone>
      <email>bpullman@dyax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
